This approval was held up for one year by the manufacturing issue at PFE’s contract fill/finish plant in McPherson, KS (#msg-128816545).
Unfortunately for MNTA, MYL received FDA approval for its own (20mg and 40mg) generic Copaxone last fall, triggering considerable price erosion in the US Copaxone market. It’s now unlikely that anybody will make much money here.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.